June 8, 2016
As Phase I clinical trials mark the first time that an investigational new drug is administered to humans, these studies are subject to appropriate current Good Manufacturing Practices (cGMP) in order to ensure patient safety.
In this blog we will explore cGMP compliance in the context of the of following functional areas.
Compliance with cGMP during manufacture of Phase I investigational drug products is established using clearly documented procedures, effective control of the manufacturing setting with respect to product environment, equipment, personnel and materials to avoid potential hazards and well recorded data from all activities related to manufacture of the drug product and all in-process and finished product testing.
Well defined activities prior to and during manufacturing are performed in order to ensure the quality of the drug product. Personnel should be trained appropriately to perform the duties for which they are responsible. Facilities used for manufacture of Phase I investigational drug product should have the appropriate work areas and necessary equipment. Work areas should be clean and provide ample space, proper lighting, ventilation, HVAC systems, plumbing and air handling systems to prevent contamination of the finished drug product. All equipment used in the manufacture of Phase 1 drug product should be identified, well maintained, calibrated, and cleaned appropriately according to the associated written procedures and these processes should be documented in the manufacturing batch record.
The Quality Control (QC) department is responsible for testing and controlling raw materials, in-process samples, finished product release testing and also for investigating unexpected results or out of specification results. Test methods should follow written procedures to evaluate specific attributes such as identity, strength, potency, and purity. Clear documentation should be maintained for all procedures, test results, and revisions to procedures. A certificate of analysis (COA) is issued for each lot of drug product which demonstrates that the material meets specified acceptance criteria for each of the attributes examined. At this stage in the development pathway however, certain attributes or acceptance criteria may not have yet been defined. Representative samples of the manufactured drug product batch should be placed into a formal stability study, as per a clearly written protocol to evaluate the product attributes as a function of time, temperature and humidity. Manufacturers should have documentation in place that outlines the roles, responsibilities and training for QC personnel and also for calibration and maintenance of laboratory equipment as applicable.
The QA team is responsible for establishing and maintaining quality systems and reviewing out of specification results and any corrective and preventative actions implemented for release of finished product and maintaining the executed batch records, among many other functions. The batch record should describe the materials, component records, equipment, procedures used, and issues observed during manufacturing, including deviations and investigations and should be detailed enough to be able to successfully reproduce the manufacturing operation. The batch record should also document if a run was terminated and what the cause was.
The Phase 1 investigational drug product should be inspected and appropriately packaged as per defined procedures to protect it from contamination or damage during storage, handling, and distribution to clinical study sites in accordance with the conditions on the label.
In summary, manufacturers of clinical trial material should have at a minimum:
April 26, 2016
In mid-April 2016, the FDA published a draft guidance clarifying the role of data integrity in current good manufacturing practice (cGMP) for drug products, as required under 21 CFR parts 210, 211,...
January 12, 2016
Over the past several years, outsourcing within the pharmaceutical supply chain has become common. The rise of the “virtual” pharmaceutical company has resulted in a complex supply chain, with the...
March 30, 2016
Evaluating the Abuse Deterrence of Generic Opioid Drug Products As we recently reported, the prevalence of opioid abuse and overdose have reached epidemic levels in the U.S. over the past decade. In...